Clinical trialObsCompleted
Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma
Prognostic Relevance of Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma
- Outcome
- Finished, no results posted
- Phase
- Obs
- Status
- Completed
- Study type
- Observational
- Start
- October 2006
- Expected end
- October 2008
- Enrollment
- 100 participants
- Sites
- 1
- Sponsor
- Other
- Results posted
- No
- Last update
- 8 July 2009
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 2
- Builds on itPancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. DOI 10.1186/1471-2407-12-527↗
- Builds on itPerioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse p… DOI 10.1186/1471-2407-11-47↗